Strides Pharma Science Reports Q2FY27 Revenue Of ₹1,429.7 Crore, Ex-US Markets Lead Growth With 31% Jump

Strides Pharma Science Ltd. disclosed its Q2FY27 financial results on Thursday, with total revenue reaching ₹1,429.7 crore, reflecting a notable 31% increase year-on-year. Of particular significance was the performance of Ex-US markets, which accounted for a substantial portion of this growth. The company's revenue for the same period last year was ₹1,220.8 crore.

EBITDA for the quarter was ₹250.9 crore, marking the first instance of crossing the ₹250 crore threshold in a quarter. This performance surpassed the EBITDA of ₹231.6 crore reported in Q2FY26. Additionally, the company's operational profit after tax (PAT) increased by 11.5% year-on-year to ₹135.8 crore, contributing to an operational EPS of ₹14.7.

The reported PAT stood at ₹134.1 crore, marking an 11.5% increase from the previous year, with a reported EPS of ₹14.2. Badree Komandur, MD and Group CEO, attributed the strong second quarter performance to the effective diversification strategy, despite challenges such as higher raw material and freight costs due to geopolitical disruptions.

In terms of financial outlook, net debt increased by ₹211.4 crore during the first half of the financial year due to factors including an elongated cash-to-cash cycle and higher inventory holding. The company anticipates that the Net Debt to EBITDA ratio will stabilize by the end of the year.